The Caring Light
for Phototherapy

Thanks to its front-line anatomic medical devices, NeoMedLight will:

  • Spread the usage of Photobiomodulation to limit side effects and increase therapeutic efficiency in cancer treatment
  • Broaden the scope of Photobiomodulation to additional therapeutic targets in specialty wound care
  • Provide a cost-effective and hospital compatible solution integrated in the therapeutic practice

NeoMedLight is certified ISO 13485.

NeoMedLight is engaged in treating and preventing mucositis and dermatitis, a huge unmet clinical need.

CareMin650
Our New Innovation

An unrivalled medical device for severe cancer treatment complications: exact & easy red-LED photobiomodulation for mucositis and dermatitis.

  • Safe treatment without side effects
  • Comfortable and painless
  • Less costly treatment alternative to laser therapy
CareMin650

Indications

Mucositis

Mucositis is a serious side effect of cancer therapy…

Read more

Radiodermatitis

Radiation dermatitis is one of the side effects of cancer radiotherapy…

Read more

Pressure Ulcer & Diabetic wounds

Hyperbilirubinemia

Phototherapy is the standard treatment for hyperbilirubinemia…

Read more

Sign up for our newsletter

And be the first to receive our latest news and updates.

You acknowledge that by submitting your email address, you agree to receive email newsletters from NeoMedLight. To see how we use your data, read our privacy policy.

Studies & Materials

View our published materials regarding phototherapy, research and our medical devices. Besides these studies, you can also access different training videos.

Studies and Materials

News

By NeoMedLight

CareMin650 is being co-financed by EU

CareMin650, previously ONCORED is being co-financed by the European Union through the Regional Development European funds.

By Joëlle Godeau

The European Commission grants 2,4M€ to NeoMedLight for its light emitting innovation which treats the lesions of patients suffering from cancers

Horizon2020 Small and Medium Enterprise Instruments (H2020 SME) award winner, the start-up NeoMedLight received a 2,4M€ grant from the European Commission for …

By THHB

Revolutionary Phototherapy System for Newborns Now Available from CMS

Central Medical Supplies Ltd (CMS) has been chosen by NeoMedLight to be the sole UK distributor for its new, innovative BiliCocoon® phototherapy …

About us

NML aims to change the field of phototherapy with a novel way to deliver therapeutic light. Based on the company unique approach to emitting light, PhotoBioModulation, a novel way to heal using light, will develop into a front line therapeutic tool for specialty wound care.

After its first step in neonatal jaundice, NeoMedLight’s primary focus is the treatment trough photobiomodulation of mucositis and dermatitis induced by chemo/radiotherapy.

Once established in that field, NeoMedLight will expend the field of indication and the range of therapeutic protocols to reach into other specialty wound care such as pressure ulcers, or diabetic wounds.

NeoMedLight has conceived and developed fiber-optic phototherapy devices to treat neonatal jaundice; as well as mucositis, dermatitis. Future projects include other specialty wound care such as pressure ulcers.

Program H2020

NeoMedLight is proud to be the recipient from a EU grant through the program H2020.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°858849.

NeoMedLight is also an ISO 13485 certified company.

European Commission logo